Prohibitins are involved in protease-activated receptor 1-mediated platelet aggregation.

Authors:
Address: Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China. zhangy@mail.kiz.ac.cn
Journal:


Publication:

abstract

BACKGROUND:

Prohibitins (PHBs), comprising the two homologous members PHB1 and PHB2, are ubiquitously expressed and highly conserved. The membrane PHBs have been reported to be involved in typhoid fever, obesity, and cancer metastasis. Proteomic studies have revealed the presence of PHBs in human platelets, but the roles of PHBs during platelet aggregation are unknown.

OBJECTIVES:

To investigate the role of PHBs in platelet aggregation.

METHODS AND RESULTS:

PHB1 and PHB2 were detected on the surfaces of human platelets by flow cytometry and confocal microscopy. The PHBs were distributed in lipid rafts, as determined by sucrose density centrifugation. In addition, the PHBs were associated with protease-activated receptor 1 (PAR1), as determined by Bm-TFF2 (a PAR1 agonist)-affinity chromatography, coimmunoprecipitation, and confocal microscopy. The platelet aggregation, α(IIb) β(3) activation, granular secretion and calcium mobilization stimulated by low concentrations of thrombin (0.05 U mL(-1)) or PAR1-activating peptide (PAR1-AP) (20 μm) were reduced or abolished as a result of the blockade of PHBs by anti-PHB antibodies or their Fab fragments; however, the same results were not obtained with induction by high concentrations of thrombin (0.6 U mL(-1)) or protease-activated receptor 4-activating peptide (300 μm). The calcium mobilization in MEG-01 megakaryocytes stimulated by PAR1-AP was significantly suppressed by PHB depletion with RNA interference against PHB1 and PHB2.

CONCLUSIONS:

PHBs are localized on the human platelet membrane and are involved in PAR1-mediated platelet aggregation. Until recently, PHBs were unknown as regulators of PAR1 signaling, and they may be effective targets for antiplatelet therapy.

© 2011 International Society on Thrombosis and Haemostasis.



Related Articles
Signaling through G(alpha)13 switch region I is essential for protease-activated receptor 1-mediated human platelet shape change, aggregation, and secretion.
J Biol Chem. 2007
Signaling through G(alpha)13 switch region I is essential for protease-activated receptor 1-mediated human platelet shape change, aggregation, and secretion.
Huang JS, Dong L, Kozasa T, Le Breton GC. J Biol Chem. 2007 Apr 6; 282(14):10210-22. Epub 2007 Feb 13.
Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation.
Ann Thorac Surg. 2006
Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation.
Day JR, Haskard DO, Taylor KM, Landis RC. Ann Thorac Surg. 2006 Feb; 81(2):619-24.
PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
J Biol Chem. 2006
PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
Holinstat M, Voss B, Bilodeau ML, McLaughlin JN, Cleator J, Hamm HE. J Biol Chem. 2006 Sep 8; 281(36):26665-74. Epub 2006 Jul 12.
[Role of adenosine diphosphate in the course of thrombin signal transmission].
Zhonghua Yi Xue Za Zhi. 2006
[Role of adenosine diphosphate in the course of thrombin signal transmission].
Han Y, Lu XX, Wang ZY, Dai L, Shen WH, Wu DP, Ruan CG. Zhonghua Yi Xue Za Zhi. 2006 Dec 12; 86(46):3299-301.
Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Blood. 2002
Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling.
Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, Cattaneo M, Kunapuli SP. Blood. 2002 May 15; 99(10):3629-36.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.